title: Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib.
abstract: OBJECTIVE
  To evaluate the functional status of patients with signs and symptoms of osteoarthritis of the knee after treatment with celecoxib compared with placebo and naproxen.
  
  
  METHODS
  Prospective, randomized, double-blind, parallel-group, 12-week trial.
  
  
  METHODS
  Multicenter study conducted at 71 sites in the United States and Canada.
  
  
  METHODS
  One thousand four patients with active osteoarthritis of the knee in a flare state.
  
  
  METHODS
  Patients were assigned randomly to one of five treatment groups: placebo; celecoxib 50 mg twice/day, 100 mg twice/day, and 200 mg twice/day; and naproxen 500 mg twice/day.
  
  
  RESULTS
  The Western Ontario and McMaster Universities Osteoarthritis Index was used to measure functional status. At the end of the treatment period, patients in the four active treatment groups had significantly better functional status than those receiving placebo. Patients treated with celecoxib 100 mg twice/day had significantly better improvements in pain scores than those treated with placebo and naproxen.
  
  
  CONCLUSIONS
  Celecoxib was better than placebo and comparable with naproxen in improving aspects of functional status in patients with osteoarthritis.
authors.affiliation: G.D. Searle & Company, Skokie, Illinois 60077, USA.
authors.forename: S Z
authors.initials: SZ
authors.lastname: Zhao
authors.forename: J I
authors.initials: JI
authors.lastname: McMillen
authors.forename: J A
authors.initials: JA
authors.lastname: Markenson
authors.forename: S D
authors.initials: SD
authors.lastname: Dedhiya
authors.forename: W W
authors.initials: WW
authors.lastname: Zhao
authors.forename: J T
authors.initials: JT
authors.lastname: Osterhaus
authors.forename: S S
authors.initials: SS
authors.lastname: Yu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000068579:Celecoxib; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D011446:Prospective Studies; D011720:Pyrazoles; D011788:Quality of Life; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib